Diabetes (type 2) - canagliflozin: evaluation report

01. Pre-meeting Briefing prepared by NICE

02. Pre-meeting Appendices prepared by NICE

03. Submission from the technology manufacturer Janssen

04. Erratum Submission from the technology manufacturer Janssen

05. NICE request to the manufacturer for clarification on their submission

06. Manufacturer clarification response

07. Consultee submission - Association of British Clinical Diabetologists (ABCD) and Royal College of Physicians (RCP)

08. Consultee submission - Royal College of Nursing

09. Clinical expert personal perspective - Matthews

10. Clinical expert statement Sathyapalan

11. Evidence Review Group report prepared by Southampton Health Technology Assessments Centre (SHTAC)

12. Erratum  Evidence Report prepared by Southampton Health Technology Assessments Centre (SHTAC)

13. Manufacturer factual accuracy check of Evidence Group Report

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

* Users of Google chrome should click the link below and then click the small PDF icon in the far right of the address bar to successfully access this document *

This page was last updated: 06 March 2014